
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5112842/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal, 2022, 28, 817-830.	3.0	2
2	Relationship between balance confidence and social engagement in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103440.	2.0	2
3	Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 637-644.	1.9	29
4	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	9.0	11
5	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology: Clinical Practice, 2021, 11, 352-357.	1.6	1
6	Gait Speed Trajectory During the Six-Minute Walk Test in Multiple Sclerosis: A Measure of Walking Endurance. Frontiers in Neurology, 2021, 12, 698599.	2.4	9
7	Evaluation of Treatment Practices for Urinalyses and Urine Cultures at an Outpatient Multiple Sclerosis Clinic. International Journal of MS Care, 2021, 23, 234-238.	1.0	3
8	Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients. PLoS ONE, 2020, 15, e0228617.	2.5	16
9	Retrospective cohort study of the relationship between systolic blood pressure variability and multiple sclerosis disability. BMJ Open, 2020, 10, e034355.	1.9	9
10	Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology, 2019, 93, e1921-e1931.	1.1	58
11	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
12	The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731984614.	1.0	9
13	Pilot study of a ketogenic diet in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e565.	6.0	82
14	Cerebellar syndrome in a man treated with natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e546.	6.0	2
15	Body mass index trajectories in pediatric multiple sclerosis. Developmental Medicine and Child Neurology, 2019, 61, 1289-1294.	2.1	21
16	Understanding the Physiological Significance of Four Inertial Gait Features in Multiple Sclerosis. IEEE Journal of Biomedical and Health Informatics, 2018, 22, 40-46.	6.3	13
17	The state of clinical research in neurology. Neurology, 2018, 90, e1347-e1354.	1.1	14
18	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238

#	Article	IF	CITATIONS
19	Real-world walking in multiple sclerosis: Separating capacity from behavior. Gait and Posture, 2018, 59, 211-216.	1.4	17
20	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Multiple Sclerosis Journal, 2018, 24, 1469-1484.	3.0	41
21	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 846-855.	27.0	201
22	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis Journal, 2017, 23, 94-105.	3.0	95
23	Remotely engaged: Lessons from remote monitoring in multiple sclerosis. International Journal of Medical Informatics, 2017, 100, 26-31.	3.3	28
24	Relationship between kernel density function estimates of gait time series and clinical data. , 2017, , .		2
25	Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Multiple Sclerosis Journal, 2017, 23, 1405-1414.	3.0	32
26	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. Journal of the American College of Radiology, 2017, 14, 371-379.e1.	1.8	49
27	Glucocorticoid-associated blood glucose response and MS relapse recovery. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e378.	6.0	3
28	Breastfeeding During Infancy Is Associated With a Lower Future Risk of Pediatric Multiple Sclerosis. Pediatric Neurology, 2017, 77, 67-72.	2.1	27
29	Demonstrating the real-world significance of the mid-swing to heel strike part of the gait cycle using spectral features. , 2017, , .		1
30	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
31	Relationship between gait variables and domains of neurologic dysfunction in multiple sclerosis using six-minute walk test. , 2016, 2016, 4959-4962.		5
32	Deepmotion: a deep convolutional neural network on inertial body sensors for gait assessment in multiple sclerosis. , 2016, , .		17
33	Adaptive symptom reporting for mobile patient-reported disability assessment. , 2016, , .		0
34	A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 8, 54-57.	2.0	34
35	Causality Analysis of Inertial Body Sensors for Multiple Sclerosis Diagnostic Enhancement. IEEE Journal of Biomedical and Health Informatics, 2016, 20, 1273-1280.	6.3	14
36	The e-MSWS-12: improving the multiple sclerosis walking scale using item response theory. Quality of Life Research, 2016, 25, 3221-3230.	3.1	16

#	Article	IF	CITATIONS
37	Quantifying six-minute walk induced gait deterioration with inertial sensors in multiple sclerosis subjects. Gait and Posture, 2016, 49, 340-345.	1.4	40
38	Fatigue and fluid hydration status in multiple sclerosis: A hypothesis. Multiple Sclerosis Journal, 2016, 22, 1438-1443.	3.0	18
39	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary Clinical Trials, 2016, 50, 166-177.	1.8	59
40	Longitudinal estimation of gait time series density in multiple sclerosis subjects using inertial data. , 2016, , .		1
41	Determining physiological significance of inertial gait features in multiple sclerosis. , 2016, , .		3
42	Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, 47-49.	2.0	30
43	PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurology: Clinical Practice, 2016, 6, e17-e19.	1.6	39
44	Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial. Clinical Therapeutics, 2015, 37, 2780-2787.	2.5	19
45	Causal analysis of inertial body sensors for enhancing gait assessment separability towards multiple sclerosis diagnosis. , 2015, , .		15
46	Multiple sclerosis, immunomodulation, and immunizations. Neurology, 2015, 84, 864-865.	1.1	3
47	Smoking Beyond Multiple Sclerosis Diagnosis. JAMA Neurology, 2015, 72, 1105.	9.0	Ο
48	Correlations between Inertial Body Sensor Measures and Clinical Measures in Multiple Sclerosis. , 2015, , .		6
49	Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis. International Journal of MS Care, 2015, 17, 138-145.	1.0	11
50	Vitamin D status and age of onset of demyelinating disease. Multiple Sclerosis and Related Disorders, 2014, 3, 684-688.	2.0	20
51	Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. Expert Review of Clinical Immunology, 2014, 10, 1281-1291.	3.0	13
52	Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opinion on Drug Safety, 2014, 13, 989-998.	2.4	32
53	Clinically meaningful performance benchmarks in MS. Neurology, 2013, 81, 1856-1863.	1.1	131
54	Clinical Importance of Steps Taken per Day among Persons with Multiple Sclerosis. PLoS ONE, 2013, 8, e73247.	2.5	65

#	Article	IF	CITATIONS
55	Evidence for the different physiological significance of the 6- and 2-minute walk tests in multiple sclerosis. BMC Neurology, 2012, 12, 6.	1.8	53
56	Validation of the NARCOMS Registry. International Journal of MS Care, 2011, 13, 114-120.	1.0	19
57	No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 264-5.	4.5	2
58	Physical inactivity, neurological disability, and cardiorespiratory fitness in multiple sclerosis. Acta Neurologica Scandinavica, 2011, 123, 98-104.	2.1	71
59	Oxygen cost of treadmill and over-ground walking in mildly disabled persons with multiple sclerosis. Neurological Sciences, 2011, 32, 255-262.	1.9	50
60	Does a waist-worn accelerometer capture intra- and inter-person variation in walking behavior among persons with multiple sclerosis?. Medical Engineering and Physics, 2010, 32, 1224-1228.	1.7	22
61	Walking impairment in patients with multiple sclerosis: exercise training as a treatment option. Neuropsychiatric Disease and Treatment, 2010, 6, 767.	2.2	61
62	Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 229-239.	3.5	125
63	Real-life walking impairment in multiple sclerosis: preliminary comparison of four methods for processing accelerometry data. Multiple Sclerosis Journal, 2010, 16, 868-877.	3.0	41
64	Multiple Sclerosis Walking Scale-12 and oxygen cost of walking. Gait and Posture, 2010, 31, 506-510.	1.4	50
65	Accelerometry and Its Association With Objective Markers of Walking Limitations in Ambulatory Adults With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2010, 91, 1942-1947.	0.9	51
66	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Multiple Sclerosis Journal, 2008, 14, 383-390.	3.0	535
67	Statins to treat multiple sclerosis. Neurology, 2008, 71, 1386-1387.	1.1	13
68	Validity of performance scales for disability assessment in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 1176-1182.	3.0	237
69	The Accuracy of Minimum Data Set Diagnoses in Describing Recent Hospitalization at Acute Care Facilities. Journal of the American Medical Directors Association, 2006, 7, 212-218.	2.5	8
70	Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease Cleveland Clinic Journal of Medicine, 2006, 73, 91-102.	1.3	52
71	Multiple sclerosis: treating symptoms, and other general medical issues Cleveland Clinic Journal of Medicine, 2006, 73, 177-186.	1.3	15
72	Misdiagnosis of Migraine. Headache, 2003, 43, 85-86.	3.9	3

5

#	Article	IF	CITATIONS
73	Leptin Indirectly Affects Estrous Cycles by Increasing Metabolic Fuel Oxidation. Hormones and Behavior, 1998, 33, 217-228.	2.1	90